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Abstract
Background
In children with symptoms suggestive of inflammatory bowel disease (IBD) who present in
primary care, the optimal test strategy for identifying those who require specialist care is
unclear. We evaluated the following three test strategies to determine which was optimal for
referring children with suspected IBD to specialist care: 1) alarm symptoms alone, 2) alarm
symptoms plus c-reactive protein, and 3) alarm symptoms plus fecal calprotectin.
Methods
A prospective cohort study was conducted, including children with chronic gastrointestinal
symptoms referred to pediatric gastroenterology. Outcome was defined as IBD confirmed
by endoscopy, or IBD ruled out by either endoscopy or unremarkable clinical 12 month fol-
low-up with no indication for endoscopy. Test strategy probabilities were generated by logis-
tic regression analyses and compared by area under the receiver operating characteristic
curves (AUC) and decision curves.
Results
We included 90 children, of whom 17 (19%) had IBD (n = 65 from primary care physicians,
n = 25 from general pediatricians). Adding fecal calprotectin to alarm symptoms increased
the AUC significantly from 0.80 (0.67–0.92) to 0.97 (0.93–1.00), but adding c-reactive pro-
tein to alarm symptoms did not increase the AUC significantly (p > 0.05). Decision curves
confirmed these patterns, showing that alarm symptoms combined with fecal calprotectin
produced the diagnostic test strategy with the highest net benefit at reasonable threshold
probabilities.
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Conclusion
In primary care, when children are identified as being at high risk for IBD, adding fecal cal-
protectin testing to alarm symptoms was the optimal strategy for improving risk stratification.
Introduction
Abdominal pain is a common gastrointestinal symptom in children that prompts a visit to the
general practitioner [1–3]. In most children, abdominal symptoms are attributed to functional
gastrointestinal disorders (FGIDs), and in a few children to an organic disease [4–6]. This dis-
tinction is important because children with FGIDs have no structural or biochemical abnor-
malities and can be managed in primary care [7,8]; moreover, excessive testing can sustain
complaints and decrease patient well-being [9,10]. However, a thorough differential diagnosis
is necessary to avoid delaying diagnosis and appropriate treatment of serious organic disease,
such as inflammatory bowel disease (IBD) [11].
Differentiation between FGID and IBD is difficult, however, because symptoms are non-
specific and frequently overlap. The absence of alarm symptoms (e.g., weight loss and rectal
blood loss) may help general practitioners to exclude IBD and prevent the unnecessary referral
of children with FGIDs [12]. However, these alarm symptoms are common and are often
related to illnesses that could be safely managed in primary care (e.g., rectal bleeding caused by
anal fissuring related to constipation). The trade-off between the benefits (early recognition of
IBD) and harms (referral of FGIDs) of referral and the lack of adequate tools to discriminate
children with IBD, triggers general practitioners to either refer children with abdominal symp-
toms for further diagnostic work-up or perform non-valid tests [4].
In primary care, evaluating alarm symptoms and blood markers is the most commonly
used diagnostic strategy for triaging children with chronic gastrointestinal symptoms before
referral to specialist care [13]. C-reactive protein has shown the best diagnostic performance
of blood markers, but evaluation of its diagnostic value is limited to highly selected children
[14,15]. More recently, fecal calprotectin has been shown to be a useful, simple, and non-inva-
sive test that can exclude IBD in primary care [16]. Although test characteristics such as sensi-
tivity, specificity, and area under the receiver operating characteristic curve (AUC) have been
presented, the added value of c-reactive protein, or fecal calprotectin to alarm symptoms are
unknown [17]. In conclusion, there is little evidence to recommend additional testing in chil-
dren with chronic gastrointestinal symptoms in primary care.
In this study, we aim to determine the optimal diagnostic test strategy supporting decisions
for referral to specialist care in children with suspected IBD by evaluating the added diagnostic
performance of c-reactive protein and fecal calprotectin beyond alarm symptoms. For that
purpose, we compared three test strategies: 1) alarm symptoms alone, 2) alarm symptoms plus
c-reactive protein, and 3) alarm symptoms plus fecal calprotectin.
Materials and methods
Setting and participants
We conducted a prospective cohort study between July 2011 and September 2014 in the Neth-
erlands. All children were followed for 12 months. We recruited 2 cohorts of children with
chronic gastrointestinal symptoms: 1) children initially seen in one out of 38 participating
general practices (primary care cohort) and 2) children initially referred by either a general
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practitioner or general pediatrician to one of the participating medical centers (4 general hos-
pitals and 3 academic centers) (referred cohort). Children included in the primary care cohort
were also included in the referred cohort when they had1 alarm symptom or an abnormal
blood test (Table 1), in accordance with the study protocol [18]. For this study we only
included children in the referred cohort.
For inclusion, children had to be aged 4–18 years and presenting with chronic diarrhea
(soft or watery stool, matching scores 5–7 of the Bristol Stool chart, for2 weeks or2 epi-
sodes in the past 6 months) [19] or recurrent abdominal pain or discomfort (2 episodes in
the past 6 months) [12,13]. An episode was defined as symptoms during three days or more.
Participants were excluded if they had a known diagnosis of chronic organic gastrointestinal
disease, had undergone endoscopic evaluation or fecal calprotectin measurement within the
preceding 6 months, or had cognitive impairment or language problems that caused difficulty
in understanding questionnaires. Furthermore, we excluded children with chronic use (>3
months) of antibiotics, non-steroid anti-inflammatory drugs (NSAID), or oral corticosteroids,
as well as children aged under 4 years, because the calprotectin levels of these groups have
been shown to be higher than those observed in healthy older children and adults [20,21].
The Medical Ethics Committee of the University Medical Centre Groningen, the Nether-
lands, approved the study. Parents of all children provided written informed consent, as did
children aged 12 years or older.
Baseline measurements
At baseline, the general practitioner or pediatrician performed a structured physical examina-
tion to identify the six alarm symptoms, using a standardized form [12,13]. A blood sample
was taken from all patients to measure four blood markers at local laboratories (c-reactive pro-
tein, hemoglobin, erythrocyte sedimentation rate, and platelet count). Directly after baseline,
Table 1. Diagnostic criteria for alarm symptoms, blood markers, and fecal calprotectin.
Symptoms or tests Measurement Positive
Alarm symptoms
Rectal blood loss History Rectal bleeding with defecation without constipation according to ROME III criteria
Family history of IBD History Affected first-degree relatives
Involuntary weight loss History and physical
examination
Involuntary decrease in weight of > 1 kg
Growth failure History and physical
examination
Target height range more than −1 standard deviation score
Extra-intestinal
symptoms
Physical examination Eyes (episcleritis, scleritis, uveitis), skin (erythema nodosum, pyoderma gangrenosum, psoriasis),
mouth ulcers, finger clubbing, arthritis
Peri-anal lesions Physical examination Skin tags, hemorrhoids, fissures, fistulas, and/or abscesses
Blood markers
Hemoglobin Local laboratory 4–12 years < 7.1 mmol/l,
boys 12–18 years < 8.1 mmol/l,
girls 12–18 years < 7.4 mmol/l [22]
C-reactive protein Local laboratory > 10 mg/l [23]
Erythrocyte
sedimentation rate
Local laboratory > 20 mm/h [23]
platelet count Local laboratory > 450 × 109/l [24]
Fecal marker
Fecal calprotectin ELISA (Phical test) > 50 μg/g
Abbreviations: ELISA: enzyme-linked immunosorbent assay; IBD: inflammatory bowel disease.
https://doi.org/10.1371/journal.pone.0189111.t001
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all children collected a stool sample that was sent to a laboratory for storage at –80˚C. At
the end of the data collection period (September 2014), calprotectin was measured in the
department of clinical chemistry at Erasmus MC Rotterdam, using a commercially available
quantitative enzyme-linked immunosorbent assay (Phical test, CALPRO AS, Oslo, Norway).
Alarm symptoms and the thresholds for blood markers and fecal calprotectin are presented in
Table 1. All physicians, researchers, and patients were blinded to the outcome of the fecal cal-
protectin test, but not to the results of alarm symptoms or blood analyses. The technicians in
all laboratories were blinded to the clinical characteristics and diagnoses of patients.
Patient flow
After baseline assessment, a pediatric gastroenterologist decided whether to perform an endos-
copy or not, based on interpretation of baseline findings and examination of the child. All
children were followed for 12 months, and every 3 months a symptom questionnaire was com-
pleted by parent or child (if aged10 years). The symptom questionnaire was developed in
cooperation with experienced pediatric gastroenterologists and general practitioners (S1 Text.
Children’s symptom questionnaire). At 12 months, either the general practitioner or pediatri-
cian performed a structured physical examination of all children who still had chronic gastro-
intestinal symptoms and who had not received a diagnosis of IBD during the study. Children
with at least one alarm symptom at this examination were seen again by the pediatric gastroen-
terologist who evaluated the need for endoscopy. If a child was lost to follow-up, the general
practitioner or pediatrician was contacted to provide updated information on relevant diagno-
ses (IBD or other organic diseases) during the 12 months after baseline.
Outcome
The diagnosis of IBD was confirmed by esophagogastroduodenoscopy and ileocolonoscopy,
with histology, according to the Porto criteria [12]. Absence of IBD was defined as no endo-
scopic and histopathologic evidence of IBD or no indication for endoscopy within or at 12
months’ follow-up. Endoscopy was not considered to be indicated if there were no alarm
symptoms for IBD or if the pediatric gastroenterologist considered that the identified alarm
symptoms were not related to IBD.
Statistical analyses
We calculated the test characteristics of alarm symptoms, blood markers and fecal calprotectin
with 95% confidence intervals (CIs). In addition, we calculated the AUC for blood markers
and fecal calprotectin.
We used logistic regression analysis to construct a basic model predicting the presence of
IBD. The dependent variable was the IBD diagnosis (dichotomous). For the independent vari-
able, we totaled the alarm symptoms into one variable (continuous) to comply with the num-
ber of events per variable (EPV) rule for obtaining adequate statistical power [25,26]. We
added weighting scores to the alarm symptoms, because the symptoms are known to have dif-
ferent predictive values [12,13].
To evaluate the added value of c-reactive protein and fecal calprotectin (both continuous
scaled) to alarm symptoms alone (basic model), the variables were added to the basic model
and their probabilities were compared to those of the basic model by calculating differences
between AUCs, using the method described by DeLong [27]. The models were also assessed
with goodness-of-fit tests and calibration plots.
We used decision curve analysis to evaluate the clinical usefulness of decision-making
based on the three diagnostic strategies [28–30]. We chose a range of threshold probabilities
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with an upper limit of 40%, because it is unrealistic that any general practitioner would accept
more than a 40% risk of IBD for a referral to be justified [17]. Strategies with the highest net
benefit at a particular threshold were considered preferable to alternative strategies.
To evaluate the verification pattern of which children received endoscopy at baseline, we
compared baseline characteristics and risk of IBD in children with and without endoscopy at
baseline. We expected that especially children at high risk would be subjected to an endoscopy.
If the distribution between variables in patients with and without missing data was differ-
ent, the data were considered missing at random (MAR) [31]. In that case, we conducted mul-
tiple imputations (fully conditional specification, predictive mean matching, [32] 20 iterations,
20 datasets), using patient characteristics, symptoms, tests and outcome as predictors [33]. We
used Rubin’s rule to calculate the pooled AUC [34]. We presented results of the non-imputed
(complete case analysis) and imputed dataset. Statistical analyses were performed with IBM
SPSS, Version 24 (IBM corp., Armonk, New York, USA) and STATA/SE 13 (STATA Corp,
College station, TX, USA).
Results
Participants
Fig 1 summarizes the patient flow in this study. Children referred to the pediatric gastroenter-
ologist by a general pediatrician (n = 25) were older, more frequently had alarm symptoms,
and were more likely to have IBD compared with children who were referred by a general
practitioner (n = 65). Children who were subject to endoscopy at baseline (n = 25) more fre-
quently had alarm symptoms, positive laboratory markers, and a high risk for IBD compared
with children who underwent no endoscopy at baseline (n = 65) (Table 2).
Diagnoses
IBD was confirmed in 17 patients (19%), of whom 7 had Crohn’s disease, 8 had ulcerative coli-
tis, and 2 had unclassified IBD. Of the 72 children (80%) with other diagnoses, 66 (73%) had a
FGID, 3 (3%) had gastroenteritis (salmonella enteric [n = 2]; Giardia lamblia [n = 1]), 1 (1%)
had reflux esophagitis, 1 (1%) had celiac disease, and 1 (1%) had a solitary rectal ulcer. In one
patient, the diagnosis was not known because the child, who was aged 16 years, refused endo-
scopic evaluation at baseline and evaluation by a general practitioner at 12 months.
Test characteristics
All tests were performed before endoscopy. The median time intervals between blood sam-
pling and endoscopy were 34 and 69 days for children with and without IBD, respectively. The
median time interval between stool sampling and endoscopy was 4 days for children with IBD
and was 8 days for children without IBD. Of the 29 children who underwent endoscopy, 11 (2
missing) had a delay of more than one month. Overall, 25 children had missing data for one
or more variable of interest. The children with and without missing data were comparable in
all baseline characteristics, except for extra-intestinal symptoms and setting (S1 Table). To
reduce the probability of selection bias, we imputed the missing data [31]. The results of the
non-imputed and imputed dataset were similar (Table 3), therefore bias is less probable and
we presented the results of the non-imputed dataset in the text.
The diagnostic characteristics of alarm symptoms, blood markers, and fecal calprotectin are
shown in S2 Table. The AUC of fecal calprotectin was 0.98 (0.96–1.00), which was significantly
higher than that for all blood markers individually (p< 0.05).
Diagnostic test strategies for inflammatory bowel disease
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Added value of C-reactive protein and fecal calprotectin
The AUC of the basic model was 0.80 (0.67–0.92). Adding c-reactive protein or fecal calprotec-
tin to the model increased the AUC to 0.88 (0.78–0.98) and 0.97 (0.93–1.00), respectively.
However, this increase was only significant for fecal calprotectin (p< 0.05) (Table 3). The
goodness-of-fit test was good for all models (Hosmer and Lemeshow test, p> 0.05). The
Fig 1. Patient flow diagram. Abbreviations: IBD: inflammatory bowel disease.
https://doi.org/10.1371/journal.pone.0189111.g001
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calibration plots of all models displayed linear concordance between the observed and pre-
dicted probabilities of IBD.
Decision curve analysis
The decision curve analysis indicates that all three diagnostic strategies had higher net benefit
at diagnostic threshold probabilities >5% when compared with the alternative of referring all
children (Fig 2). Alarm symptoms in combination with fecal calprotectin had the highest net
benefit at threshold probabilities between 5% and 40%. Table 4 shows that the test strategy of
alarm symptoms plus fecal calprotectin generated a higher reduction in the numbers of refer-
rals without missing a child with IBD at different threshold probabilities compared to all other
strategies.
Table 2. Baseline characteristics of children by referrer and whether endoscopy was performed at baseline.
Referred by general
practitioners
(n = 65)
Referred by general
pediatrician
(n = 25)
No endoscopy At
baseline
(n = 65)
Endoscopy At
baseline
(n = 25)
Male sex (n (%)) 29 (45) 8 (32) 27 (42) 10 (40)
Age in years at baseline (median,
IQR)
10 (7–14) 14 (10–15.5) 9 (6–14) 15 (12–16)
Duration symptoms (n (%))
<0.5 year 14 (22) 6 (24) 12 (19) 8 (32)
>1 year 41 (63) 9 (36) 42 (65) 8 (32)
History and physical examination
(n (%))
Growth failure 6 (9.2) 0 (0) 5 (8) 1 (4)
Involuntary weight loss 10 (15) 13 (52) 10 (15) 13 (52)
Rectal blood loss 13 (20) 14 (56) 16 (25) 11 (44)
Positive family history of IBD 9/64 (14) 2 (8) 6/64 (9) 5 (20)
Extra-intestinal symptoms 4 (6) 9 (36) 6 (9) 7 (28)
Peri-anal lesions 9 (14) 4/24 (17) 7 (11) 6/24 (25)
1 alarm symptoms 38 (59) 24 (96) 39 (60) 23 (92)
Blood markers (n (%))
hemoglobin (cut-off is age/sex
specifica)
5/61 (8) 6/24 (25) 4/61 (7) 7/24 (29)
C-reactive protein (>10 mg/l) 5/56 (9) 5/19 (26) 2/53 (4) 8/22 (36)
erythrocyte sedimentation rate (>20
mm/h)
8/59 (14) 8/24 (33) 4/59 (7) 12/24 (50)
Platelet count (>450 x109/l) 4/61 (7) 3/24 (13) 4/61 (7) 3/24 (13)
1 blood marker 14/53 (28) 10/19 (53) 11/50 (22) 13/22 (59)
Fecal test (n (%))
fecal calprotectin (>50 μg/g) 14/63 (22) 13/22 (59) 9/63 (14) 18/22 (82)
Reference standard (n (%))
endoscopy 9 (14) 20 (80) 4 (6) 25 (100)
Diagnoses (n (%))
IBD 5 (8) 12 (48) 2 (3) 15 (60)
FGIDsb 55 (85) 11 (44) 58 (89) 8 (32)
a 4–12 years < 7.1 mmol/l, boys 12–18 years < 8.1 mmol/l, girls 12–18 years < 7.4 mmol/l.
b Diagnosis of FGID was reached when after 12 months there were no signs of any inflammatory, anatomic, metabolic, or neoplastic pathology after
thorough history, physical examination, and additional testing by the treating physician.
Abbreviations: FGID: functional gastrointestinal disorder; IBD: inflammatory bowel disease.
https://doi.org/10.1371/journal.pone.0189111.t002
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Table 3. The various diagnostic models for IBD with the non-imputed and imputed datasets.
Non-imputed
DOR
(95% CI)
Imputed
Pooled DOR
(95% CI)
Non-imputed
AUC
(95% CI)
Imputed
Pooled AUC
(95% CI)
Alarm symptoms 1.02 (1.01–1.04) 1.02 (1.01–1.04) 0.80 (0.67–0.92) 0.80 (0.69–0.90)
Alarm symptoms + c-reactive protein 1.02 (1.01–1.04) 1.02 (1.01–1.03) 0.88(0.78–0.98) 0.85(0.76–0.93)
1.18 (1.04–1.33) 1.14 (1.01–1.27)
Alarm symptoms + fecal calprotectin 1.01 (0.99–1.04) 1.02 (0.99–1.04) 0.97(0.93–1.00) 0.97(0.93–1.00)
1.01 (1.003–1.02) 1.01 (1.003–1.03)
Basic model consisted of the number of weighted alarm symptoms (Total score: 357): growth failure (weight: 51), involuntary weight loss (weight: 44), rectal
blood loss (weight: 60), family history of IBD (weight: 53), extra-intestinal symptoms (weight: 78), peri-anal lesions (weight: 71). The mean weighting scores
for the alarm symptoms were based on the independent opinions of 85 physicians who treat children with chronic gastrointestinal symptoms in different
clinical settings. The physicians weighted the alarm symptoms using a visual analog scale from 0 (completely excludes that the child has IBD) to 100
(absolutely confirms that the child has IBD). Interpretation DOR: one point increase on a continuous scaled test result (weighted alarm symptoms, c-reactive
protein, fecal calprotectin) increases the risk of IBD with the DOR-value. Abbreviations: DOR: Diagnostic Odds Ratio; AUC: area under the curve.
https://doi.org/10.1371/journal.pone.0189111.t003
Fig 2. Decision curve for the three models predicting the outcome of IBD in the non-imputed dataset. Representative interpretation
of the decision curve: the purple line representing the alarm symptoms + fecal calprotectin strategy shows a net benefit of 0.16 at a
threshold probability of 20%. In this instance, a threshold probability of 20% means that a general practitioner would be willing to refer 5
children to prevent a delay in diagnosis for 1 child with IBD. The net benefit of 0.16 means that this strategy would lead to the referral of 160
per 1000 children at risk, with all referrals having IBD. Abbreviations: CRP: C-reactive protein, FCal: fecal calprotectin.
https://doi.org/10.1371/journal.pone.0189111.g002
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Discussion
In this study, 73% of children referred for evaluation of chronic gastrointestinal symptoms had
FGIDs that could be managed in primary care, and the prevalence of IBD was 19%. Interest-
ingly, for children in whom general practitioners considered a referral for further diagnostic
work-up, c-reactive protein provided no additional diagnostic value when used in combina-
tion with alarm symptoms. By contrast, the addition of fecal calprotectin to alarm symptoms
significantly improved the AUC. Compared to the strategy of adding c-reactive protein to
alarm symptoms, adding fecal calprotectin to alarm symptoms showed the highest net benefit
and produced the greatest reduction in the number of referrals for IBD without any false
negatives.
In clinical practice, physicians use diagnostic threshold probabilities to determine when
they need to initiate further testing before deciding on further management. The decision
curve analysis in this study indicated, that in children with a threshold probability of IBD that
was< 5%, testing with c-reactive protein or fecal calprotectin had limited additional value.
Therefore, we advise against testing c-reactive protein or fecal calprotectin in children with a
very low risk for IBD (e.g. without alarm symptoms). At threshold probabilities between 5%
and 40%, however, the test strategy with alarm symptoms and fecal calprotectin showed high-
est net benefit. Moreover, the discriminative power of fecal calprotectin proved to be superior
to all blood markers when compared individually. Therefore, on the bases of our results, we
conclude that fecal calprotectin is the best laboratory test for use when seeking to further strat-
ify children identified as at risk for IBD by history and physical examination. In our previous
study in primary care, we showed that a calprotectin value below 50 μg/g feces can safely
exclude IBD [16]. Therefore, a normal calprotectin value is a very reassuring test result that
complements a thorough history and physical examination in children with chronic gastroin-
testinal symptoms. It is important that the GP is aware of factors that increase the fecal calpro-
tectin value: the calprotectin value is increased in children with bacterial gastroenteritis,
younger than four years, or using NSAIDs or antibiotics [21].
There are few publications about the added value for fecal calprotectin in children with
symptoms suggestive of IBD. A study evaluating the added value of fecal calprotectin using the
“clinical eye” of the pediatrician showed that fecal calprotectin reduced the need for referral to
a pediatric gastroenterologist, with only a low risk of missing a child with IBD [23]. However,
we could not determine how this approach incorporated alarm symptoms and blood markers.
Other researchers constructed a model to predict the risk of having IBD based on fecal calpro-
tectin and age,[35] and correctly identified 85.5% of children with a sensitivity of 0.81 and
specificity of 0.92 (AUC 0.92). However, important predictors, such as alarm symptoms and
blood markers, were not included in their model.
It is important to realize that our study included patients referred by general practitioners
and general pediatricians. Although it was assumed that these represent the same patient
Table 4. Reduction in referral rate for further diagnostic work-up per 100 children using different threshold probabilities for the three test
strategies.
Threshold probability Alarm symptoms Alarm symptoms + c-reactive protein Alarm symptoms + fecal calprotectin
10% – 15 32
15% 12 33 49
20% 35 40 59
Note: The reduction in the number of referral for further diagnostic work-up per 100 children without missing a child with IBD was calculated as follows: (net
benefit strategy—net benefit of refer all) / [Pt / (1 –Pt)] × 100.
https://doi.org/10.1371/journal.pone.0189111.t004
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population, the children referred by a pediatrician were more likely to have IBD, were older,
and had more alarm symptoms compared with children referred by their general practitioner.
This result is to be expected in the Dutch healthcare system, because pediatricians can only be
consulted if patients are referred by a general practitioner, but pediatric gastroenterologists
can be consulted if children are referred by either a general practitioner or a general pediatri-
cian. Healthcare systems in the United Kingdom, Scandinavia, Canada, New Zealand, and
Australia are similar [36].
A limitation of our study is that alarm symptoms are routinely assessed with blood markers
in children with symptoms suggestive of IBD. Consequently, the reference standard was inter-
preted with prior knowledge of the test results of alarm symptoms and blood markers, which
might have caused review bias and overestimation of the diagnostic accuracy of the alarm
symptoms and blood markers [37]. Another limitation is that we did not perform endoscopies
in children with a low likelihood of IBD, because this was considered unethical. There are two
important aspects to consider when assessing whether the use of two reference standards lead
to biased accuracy estimates: the verification pattern and the appropriateness of the follow-up
[38]. Although the verification pattern was based on the clinical judgment of the pediatric
gastroenterologist, and was thereby somewhat subjective, our results did show that children
who received endoscopy at baseline were at higher risk for IBD than children who received fol-
low-up. Therefore, if the test strategies were only evaluated in the children who received endos-
copy at baseline, the results would probably be biased [39]. Although IBD is not a self-limiting
disease and it is very rare for it to stay in remission for one year,[23] there is a very small chance
that we missed a child with IBD; such data could alter the diagnostic values reported for the
tests. However, follow-up is the best achievable option given the reality of clinical care [40].
Given that there were few children with IBD in our study (n = 17), we combined the
weighted alarm symptoms into one variable based on the subjective opinions of 85 physicians.
Despite this, the AUC of the combined alarm symptoms without weighting was comparable to
that with weighting. We also evaluated the added value of two important markers based on
eight events per variable; although it is recommend to have at least 10 events per variable it has
been shown that 5 events per variable is appropriate [25]. A larger study with more events is
needed for the development of a prediction model for IBD based on single alarm symptoms,
blood markers, and fecal calprotectin results [29]. Moreover, an exploration of whether age
influences the prediction model is needed.
Conclusions
The addition of fecal calprotectin to an evaluation of alarm symptoms was the optimal strategy
for stratifying children identified as being at risk of IBD by their general practitioner. This
strategy is different to that published in several guidelines, which recommend testing for c-
reactive protein and other blood markers of inflammation when alarm symptoms are present
[13,41]. It should be noted that we focused on IBD alone in this study, whereas general practi-
tioners must evaluate whether symptoms are related to any organic disease, including celiac
disease. Further studies are therefore needed to investigate whether the new test strategy com-
bining the assessment of alarm symptoms with testing for fecal calprotectin can improve deci-
sion-making in clinical practice. These studies should also include a cost–benefit analysis.
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